MYELODYSPLASTIC SYNDROMES

This study tested an experimental drug called MBG453 for adults with a lower-risk form of myelodysplastic syndromes (MDS), a bone marrow disorder. The drug is designed to help the patient's own immune system better recognize and attack the abnormal blood cells. The trial was for …

This early-stage study aimed to find a safe dose and check for side effects of an experimental drug called CC-95251. It was tested alone and combined with other cancer drugs in 56 adults with advanced or returning forms of acute myeloid leukemia (AML) and myelodysplastic syndrome…

This early-stage study tested a new drug, BMS-986253, for adults with myelodysplastic syndromes (MDS), a serious bone marrow disorder. The goal was to see if the drug was safe and could help control the disease, either alone or combined with standard medications. The trial was te…

This early-stage study aimed to test the safety and initial effectiveness of a new drug called SL-172154. It was given alone or combined with standard drugs (azacitidine and/or venetoclax) to adults with higher-risk forms of myelodysplastic syndromes (MDS) or acute myeloid leukem…

This early-stage study aimed to find safe doses for several single drugs and drug combinations in adults with lower-risk myelodysplastic syndrome (MDS), a bone marrow disorder. The trial enrolled 33 participants to test the safety and tolerability of these treatments. It was term…

This early-stage study tested whether specially prepared stem cells could safely prevent graft-versus-host disease (GVHD) in patients receiving bone marrow transplants for blood cancers. GVHD is a serious and common complication where the donor's immune cells attack the patient's…

This study tested an experimental cell therapy called TCB008 for adults with acute myeloid leukemia (AML) or related conditions where the cancer has returned or not responded to standard treatments. The therapy involves infusing specially grown immune cells from healthy donors to…

This study tested whether adding an experimental drug called MBG453 to the standard treatment (azacitidine) could help adults with higher-risk forms of myelodysplastic syndromes (MDS) or a related blood cancer (CMML-2). The main goal was to see if the combination helped patients …

This study was the first time a new drug called SAR443579 was tested in people. It aimed to find a safe dose and see if it could help control several aggressive blood cancers that had come back or stopped responding to other treatments. The trial included both adults and children…

This early-phase study tested a new drug called INCB000928 to see if it could safely treat anemia (low red blood cells) in people with myelodysplastic syndromes (MDS) or multiple myeloma. The main goals were to find a safe dose and see if the drug could reduce the need for blood …

This early-phase trial tested a new combination of two oral drugs, eltanexor and Inqovi, for adults with high-risk myelodysplastic syndromes (MDS), a serious bone marrow disorder that can lead to leukemia. The study aimed to find a safe, effective dose and see if the combo could …

This study tested whether adding an experimental drug called MBG453 to standard chemotherapy could better control a serious blood and bone marrow disorder called myelodysplastic syndrome (MDS). It involved 127 adults with intermediate to very high-risk MDS who were not candidates…

This early-stage study tested a new drug called DSP107, given alongside standard cancer drugs, for patients with hard-to-treat forms of leukemia and related blood disorders. The main goals were to find a safe dose and see if the combination could help control the disease. The stu…